A recombinant Avibacterium paragallinarum type A HMTP protein, vaccine composition and application thereof

By processing the HMTP210 protein through cleavage and fusion of antigenic epitopes, the problems of expression difficulties and insufficient protective efficacy were solved. The resulting genetically engineered subunit vaccine has significant protective efficacy against infectious coryza in chickens, especially when mixed with aroA protein.

CN118388607BActive Publication Date: 2024-11-26JINGZHOU CHANGXIN BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410769555.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-06-14
Publication Date
2024-11-26
Estimated Expiration
2044-06-14

AI Technical Summary

Technical Problem

Existing inactivated vaccines for infectious coryza in chickens suffer from problems such as difficulty in cultivation, high cost, inconsistent protective efficacy, and severe side effects. Furthermore, the HMTP210 protein is expressed at low levels in prokaryotes and is prone to forming inclusion bodies, which affects the protective efficacy of the vaccine.

Method used

By cleaving the N-terminal 147 amino acid residues of the HMTP210 protein of Bacillus paragallinarum type A, retaining the amino acid sequence from position 148 to 666, and fusing an antigenic epitope sequence at its N-terminus, recombinant Bacillus paragallinarum type A HMTP protein was prepared. Codon optimization was then used to improve solubility and immunogenicity, thus preparing a genetically engineered subunit vaccine.

Benefits of technology

The solubility and immunogenicity of recombinant Avian bacillus paragallinarum HMTP protein were improved, and the prepared genetically engineered subunit vaccine had good protective efficacy against infectious coryza in chickens. The protective efficacy was further enhanced when mixed with aroA protein.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118388607B_ABST
    Figure CN118388607B_ABST
Patent Text Reader

Abstract

The invention discloses a recombinant A type A bacterium paragallinarum HMTP protein, a vaccine composition and its application, and belongs to the technical field of veterinary biological products. The invention is to remove 147 amino acid residues from the N-terminal of the A type A bacterium paragallinarum HMTP210 protein as shown in SEQ ID NO.3, and obtain the core sequence of the 148-666 amino acid sequence, and then obtain the recombinant A type A bacterium paragallinarum HMTP protein after fusing the antigen epitope sequence at the N-terminal of the core sequence, and the recombinant A type A bacterium paragallinarum HMTP protein has good solubility and good immunogenicity, and after being prepared into a genetically engineered subunit vaccine, it has good protective efficacy against chicken infectious coryza (type A). Further, after the recombinant A type A bacterium paragallinarum HMTP protein and the recombinant A type A bacterium paragallinarum aroA protein are mixed in a specific ratio, the prepared genetically engineered subunit vaccine composition has better protective efficacy against chicken infectious coryza (type A).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of veterinary biological products, and specifically relates to a recombinant A. paragallinarum HMTP protein, a vaccine composition and applications thereof. Background Art

[0002] Infectious coryza is an avian respiratory disease caused by A. paragallinarum infection. It is most common in growing chickens and laying hens aged 1 to 4 months. It causes the occurrence of yolk peritonitis in growing chickens and leads to large-scale culling, softening of follicles and hematoma in laying hens, and a sharp drop in egg production. Chickens infected with A. paragallinarum generally do not die, but once mixed with other pathogenic microorganisms, the mortality rate of sick chickens increases significantly.

[0003] According to the plate agglutination test, A. paragallinarum can be divided into three serotypes: A, B and C. These three serotypes have been detected in my country, and the infection rate has shown an upward trend. Among them, type A is the serotype with the longest existence and the most serious harm in my country. At present, the prevention and control of infectious coryza in chickens mainly adopts the inactivated vaccine of A. paragallinarum. However, there are three major problems in the production, preparation and application of the inactivated vaccine of A. paragallinarum: (1) The in vitro culture of A. paragallinarum requires the addition of NAD and serum, which has high nutritional requirements, is difficult to culture and has high costs; (2) The serotype of the strain of the inactivated vaccine of infectious coryza in chickens may be inconsistent with the serotype of the epidemic strain, and cannot provide cross-protection; (3) The inactivated vaccine of infectious coryza in chickens contains a large amount of endotoxins, bacterial virulence proteins and other additives, which are easy to cause serious side effects after vaccination. These factors have led to the current unsatisfactory prevention and control of the disease in my country.

[0004] HMTP210 is the main hemagglutinin factor of Avibacterium paragallinarum and an important virulence factor. The complete HMTP210 antigen can fold into a trimer structure and induce the body to produce protective antibodies. However, HMTP210 has a large molecular weight and contains many hydrophobic amino acids at the N-terminus, which makes it difficult to express using a prokaryotic expression system. Not only is the expression level low, but it is also easy to form inclusion bodies.

[0005] In order to solve the above problems, the current conventional practice is to delete some amino acids at the N-terminus of HMTP210. After this treatment, not only the expression level is improved, the solubility is increased, but also the normal trimer structure is maintained. However, after deleting some amino acids at the N-terminus of the HMTP210 protein, some important antigenic epitopes will be lost, so that the genetically engineered subunit vaccine prepared from this antigen has a problem of varying degrees of reduced protective efficacy against chicken infectious coryza (type A). Summary of the invention

[0006] The object of the present invention is to provide a recombinant A. paragallinarum HMTP protein, a vaccine composition and its application. The present invention obtains a core sequence of the amino acid sequence at positions 148-666 by cutting 147 amino acid residues from the N-terminus of the A. paragallinarum HMTP210 protein as shown in SEQ ID NO.3, and then obtains a recombinant A. paragallinarum HMTP protein after fusing an antigen epitope sequence to the N-terminus of the core sequence. The recombinant A. paragallinarum HMTP protein has good solubility and good immunogenicity. After being prepared into a genetically engineered subunit vaccine, it has good protective efficacy against infectious coryza (type A) in chickens.

[0007] In a first aspect, the present invention provides a recombinant A type A Avian Bacillus paragallinarum HMTP protein, wherein the recombinant A type A Avian Bacillus paragallinarum HMTP protein is obtained by shearing off 147 amino acid residues from the N-terminus of the A type A Avian Bacillus paragallinarum HMTP210 protein as shown in SEQ ID NO.3 to obtain a core sequence of the amino acid sequence at positions 148-666, and then fusing an antigenic epitope sequence to the N-terminus of the core sequence; wherein the antigenic epitope sequence is selected from at least one of the amino acid sequences at positions 6-12, 22-36, 60-67, 75-86, 93-100, and 103-112 of the Avian Bacillus paragallinarum HMTP210 protein as shown in SEQ ID NO.3.

[0008] In the present invention, the inventors have found that the recombinant A. paragallinarum HMTP protein obtained by removing the N-terminal amino acid sequence of positions 1-147 of the A. paragallinarum HMTP210 protein and fusing the antigenic epitope sequence not only has a significantly increased soluble expression level, but also further improves the immunogenicity of the recombinant A. paragallinarum HMTP protein after fusing the antigenic epitope sequence.

[0009] Specifically, in the present invention, the antigenic epitope sequence can be selected from, for example, the 6-12 amino acid sequence, the 22-36 amino acid sequence, the 60-67 amino acid sequence, the 75-86 amino acid sequence, the 93-100 amino acid sequence, and the 103-112 amino acid sequence of the A. paragallinarum HMTP210 protein as shown in SEQ ID NO. 3. One, or two, or three, or four, or five, or six. When multiple antigenic epitope sequences of the A. paragallinarum HMTP210 protein as shown in SEQ ID NO. 3 are selected, the connection order of the multiple antigenic epitope sequences can be arbitrarily combined.

[0010] In some embodiments, the antigenic epitope sequence includes the amino acid sequence at positions 75-86 and the amino acid sequence at positions 103-112 of the Avibacterium paragallinarum HMTP210 protein of type A as shown in SEQ ID NO.3; the fusion operation includes: connecting using a linker, and the amino acid sequence of the linker is shown in SEQ ID NO.4.

[0011] In the present invention, the inventors further studied and found that the positions of the amino acid sequence at positions 75-86 and the amino acid sequence at positions 103-112 of the A. paragallinarum HMTP210 protein of type A as shown in SEQ ID NO.3 are relatively close and the antigenic epitope is large, therefore, it is preferred that the above two antigenic epitope sequences are fused, and the obtained recombinant A. paragallinarum HMTP protein has a higher soluble expression amount and better immunogenicity. Linker is used to connect the amino acid sequence at positions 75-86 and the antigenic epitope sequence of the A. paragallinarum HMTP210 protein of type A as shown in SEQ ID NO.3, and to connect multiple antigenic epitope sequences.

[0012] In some embodiments, the amino acid sequence of the recombinant A. paragallinarum type A HMTP protein is shown as SEQ ID NO.1.

[0013] The above-mentioned recombinant A. paragallinarum type A HMTP protein provided by the present invention can be a natural, recombinant or synthetic active polypeptide, and the active polypeptide can be a naturally purified product, a chemically synthesized product, or a product produced from a prokaryotic host (such as Escherichia coli) or a eukaryotic host (such as yeast, higher plants) using recombinant technology.

[0014] In some embodiments, the above-mentioned recombinant A. paragallinarum type A HMTP protein is obtained by introducing a recombinant vector containing its encoding gene into an expression host (such as Escherichia coli BL21 (DE3)) to obtain a recombinant genetically engineered strain, and then culturing the recombinant genetically engineered strain and inducing expression to obtain the recombinant A. paragallinarum type A HMTP protein.

[0015] In a second aspect, the present invention provides a nucleic acid molecule encoding the above-mentioned recombinant A. paragallinarum type A HMTP protein, the nucleotide sequence of the nucleic acid molecule being as shown in SEQ ID NO.5 or SEQ ID NO.6; wherein, the nucleotide sequence as shown in SEQ ID NO.6 is obtained by codon-optimizing the nucleotide sequence as shown in SEQ ID NO.5.

[0016] In some preferred embodiments, the nucleotide sequence of the nucleic acid molecule is shown as SEQ ID NO.6.

[0017] In the present invention, in order to increase the expression amount and solubility level of prokaryotic expression, the above-mentioned SEQ ID The nucleotide sequence shown in NO.5 is codon optimized; specifically, the codon optimization includes optimizing one or more of the amino acid residues encoding positions 59, 61, 89, 90, 102, 179, 237, 339, 346, 366, 367, 381, 407, 460 and 509; preferably, the codon optimization includes: the codon ATA at position 59 is synonymously replaced by the codon ATT that can be normally recognized by Escherichia coli tRNA, the codon CTA at position 179 is synonymously replaced by the codon CTG that can be normally recognized by Escherichia coli tRNA, the codon AGA at position 237 is synonymously replaced by the codon AGC that can be normally recognized by Escherichia coli tRNA, the codon CTA at position 381 is synonymously replaced by the codon CTG that can be normally recognized by Escherichia coli tRNA, and the codon CTA at position 407 is synonymously replaced by the codon CTG that can be normally recognized by Escherichia coli tRNA.

[0018] After the above codon optimization, the nucleotide sequence shown as SEQ ID NO.6 was obtained.

[0019] The nucleic acid molecules provided by the present invention can usually be obtained by PCR amplification or artificial synthesis.

[0020] In a third aspect, the present invention provides a biomaterial, which is selected from any one of the following: A1) an expression cassette comprising the above nucleic acid molecule; A2) a recombinant vector comprising the above nucleic acid molecule; A3) a recombinant cell comprising the above nucleic acid molecule or the above recombinant vector.

[0021] In the present invention, the expression cassette may further include regulatory elements and enhancing elements; the recombinant vector includes a cloning vector and an expression vector, the cloning vector is used to replicate related sequences, and the expression vector is used to express related genes, wherein the vector used to construct the expression vector may be PET28a; the recombinant cell may be Escherichia coli BL21 (DE3).

[0022] In a fourth aspect, the present invention provides a genetically engineered subunit vaccine for infectious coryza (type A) in chickens, comprising any of the above-mentioned recombinant Avibacterium paragallinarum type A HMTP proteins.

[0023] In some embodiments, the genetically engineered subunit vaccine further comprises a medically acceptable carrier, and the medically acceptable carrier comprises an adjuvant.

[0024] In some preferred embodiments, the adjuvant is ISA71VG.

[0025] In some preferred embodiments, the content of recombinant A. paragallinarum type A HMTP protein is ≥25 μg / mL, for example, it can be 25 μg / mL, 50 μg / mL, or 100 μg / mL, and the volume ratio of the recombinant A. paragallinarum type A HMTP protein to the adjuvant is preferably 1:3.

[0026] In the fifth aspect, the present invention provides a genetically engineered subunit vaccine composition for infectious coryza (type A) in chickens, comprising any of the above-mentioned recombinant type A Avibacterium paragallinarum HMTP protein, recombinant type A Avibacterium paragallinarum aroA protein and a medically acceptable carrier; wherein the amino acid sequence of the recombinant type A Avibacterium paragallinarum aroA protein is shown in SEQ ID NO.2, and the nucleotide sequence of the nucleic acid molecule encoding the recombinant type A Avibacterium paragallinarum aroA protein is shown in SEQ ID NO.7.

[0027] The above-mentioned recombinant A. paragallinarum type AroA protein provided by the present invention can be a natural, recombinant or synthetic active polypeptide, and the active polypeptide can be a naturally purified product, a chemically synthesized product, or a product produced from a prokaryotic host (such as Escherichia coli) or a eukaryotic host (such as yeast, higher plants) using recombinant technology.

[0028] In some embodiments, the above-mentioned recombinant A. paragallinarum aroA protein is obtained by introducing a recombinant vector containing its encoding gene into an expression host (such as Escherichia coli BL21 (DE3)) to obtain a recombinant genetically engineered strain, and then culturing the recombinant genetically engineered strain and inducing expression to obtain the recombinant A. paragallinarum aroA protein.

[0029] The nucleic acid molecule encoding the recombinant Avibacterium paragallinarum type A aroA protein provided by the present invention can usually be obtained by PCR amplification or artificial synthesis.

[0030] In some preferred embodiments, in the above-mentioned genetically engineered subunit vaccine composition, the content of recombinant A. paragallinarum type A HMTP protein is ≥25 μg / mL, and the content of recombinant A. paragallinarum type A aroA protein is ≥25 μg / mL.

[0031] In some more preferred embodiments, the content of the recombinant A. paragallinarum type A HMTP protein is ≥100 μg / mL, and the content of the recombinant A. paragallinarum type A aroA protein is ≥50 μg / mL.

[0032] In the present invention, the inventors further discovered that after mixing the recombinant A. paragallinarum HMTP protein with the recombinant A. paragallinarum aroA protein, the genetically engineered subunit vaccine composition prepared has better protective efficacy against infectious coryza (type A) in chickens.

[0033] In the sixth aspect, the present invention provides a method for preparing the above-mentioned genetically engineered subunit vaccine composition for infectious coryza (type A), comprising the following steps: S1, constructing a recombinant vector containing a nucleic acid molecule encoding a recombinant type A Avian Bacillus paragallinarum HMTP protein and a nucleic acid molecule encoding a recombinant type A Avian Bacillus paragallinarum aroA protein, respectively, and then transforming them into host cells to obtain recombinant cells; S2, culturing the recombinant cells, inducing expression to obtain a culture, and separating and purifying from the culture to obtain a recombinant type A Avian Bacillus paragallinarum HMTP protein and a recombinant type A Avian Bacillus paragallinarum aroA protein, respectively; S3, mixing the recombinant type A Avian Bacillus paragallinarum HMTP protein and / or the recombinant type A Avian Bacillus paragallinarum aroA protein with an adjuvant to obtain a genetically engineered subunit vaccine composition for infectious coryza (type A).

[0034] In the present invention, there are no special requirements for the culture method and culture conditions, as long as the normal growth of the recombinant cells is ensured. And the methods for isolating the above-mentioned recombinant A. paragallinarum HMTP protein and recombinant A. paragallinarum aroA protein from the culture are conventional methods in the art.

[0035] In some preferred embodiments, the recombinant A. paragallinarum HMTP protein is purified by a weak cation exchange chromatography method; and the recombinant A. paragallinarum aroA protein is purified by a weak anion exchange chromatography method.

[0036] In some embodiments, the culture medium used in the preparation method of the recombinant A. paragallinarum type A HMTP protein and the recombinant A. paragallinarum type A aroA protein is a culture medium that can express proteins in the art, preferably LB culture medium.

[0037] In the seventh aspect, the present invention provides the use of any of the above-mentioned recombinant Avibacterium paragallinarum type A HMTP proteins, the above-mentioned nucleic acid molecules, the above-mentioned biological materials, the above-mentioned chicken infectious coryza (type A) genetically engineered subunit vaccines, and the above-mentioned chicken infectious coryza (type A) genetically engineered subunit vaccine compositions in the preparation of drugs for preventing and / or treating chicken infectious coryza (type A).

[0038] The beneficial effect of the present invention is that, different from the prior art, the present invention is to cut off 147 amino acid residues from the N-terminus of the A-type Avian bacterium paragallinarum HMTP210 protein as shown in SEQ ID NO.3 to obtain a core sequence of the amino acid sequence at positions 148-666, and then fuse an antigen epitope sequence to the N-terminus of the core sequence to obtain a recombinant A-type Avian bacterium paragallinarum HMTP protein. The recombinant A-type Avian bacterium paragallinarum HMTP protein has good solubility and good immunogenicity. After being prepared into a genetically engineered subunit vaccine, the recombinant Avian bacterium paragallinarum HMTP protein has good protective efficacy against infectious coryza (type A) in chickens. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 The SDS-PAGE diagram of the protein expressed before and after codon optimization of the HMTP gene of Avibacterium paragallinarum type A in Example 2 of the present invention, wherein lane M: protein marker; lane 1: negative control; lane 2: soluble protein expressed before codon optimization (HMTP); lane 3: total protein expressed before codon optimization (HMTP); lane 4: soluble protein expressed after codon optimization (HMTPopti); lane 5: total protein expressed after codon optimization (HMTPopti);

[0040] Figure 2 This is an SDS-PAGE image of the recombinant A. paragallinarum HMTP protein purified in Example 2 of the present invention, wherein lane M: protein marker; lane 1: negative control; lanes 2 and 3: recombinant A. paragallinarum HMTP protein before purification; lane 4: recombinant A. paragallinarum HMTP protein after purification;

[0041] Figure 3 This is an SDS-PAGE image of the recombinant A. paragallinarum aroA protein purified in Example 3 of the present invention, wherein lane M: protein marker; lane 1: negative control; lane 2: recombinant A. paragallinarum aroA protein before purification; lane 3: recombinant A. paragallinarum aroA protein after purification. DETAILED DESCRIPTION

[0042] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0043] The experimental methods without specific conditions in the examples are usually carried out according to conventional experimental methods in the field of molecular biology, including but not limited to the experimental methods described in Molecular Cloning: A Laboratory Manual by MR Green, Molecular Biology by Robert F. Weaver, etc., or according to the experimental methods recommended by the kit and instrument manufacturers. The reagents and biological materials used in the examples can be obtained from commercial channels unless otherwise specified.

[0044] Example 1 Cloning, sequence optimization, construction of expression strain and prokaryotic expression purification of A. paragallinarum HMTP gene

[0045] 1.1 Cloning and sequencing of the full-length gene of A. paragallinarum HMTP210

[0046] 1.1.1 Extraction of the genome of A. paragallinarum HP-8 strain

[0047] Take 0.2 ml of A. paragallinarum HP-8 bacterial solution, centrifuge at 8000 g for 5 min, discard the supernatant, add 50 μL of ddH2O to resuspend; boil at 100° C. for 10 min, centrifuge at 8000 g for 5 min, and take the supernatant and store at -20° C. The supernatant contains the genome of A. paragallinarum HP-8 strain, which is the template for PCR amplification.

[0048] 1.1.2 PCR amplification of the full-length A. paragallinarum HMTP210 gene fragment

[0049] First, the primers for amplifying the full-length A. paragallinarum HMTP210 gene fragment were synthesized as follows:

[0050] HMTP F1:5'-ATTCGGATACCTCAATGAC-3'(SEQ ID NO.10)

[0051] HMTP R1:5'- CCC CTCGAG TTATTGAGTGCTAGATGCTGTAG-3'(SEQ ID NO.11)

[0052] The italic part is the introduced protective base, and the underlined part is the introduced Xho I restriction site. The genome of the extracted A. paragallinarum HP-8 strain was used as a template, and the full-length A. paragallinarum HMTP210 gene fragment was amplified using HMTP F1 / HMTP R1 as primers. The amplification system is as follows:

[0053] Set the temperature cycle parameters: 95°C, 2 min; 35 cycles (95°C, 20 s; 60°C, 20 s; 72°C, 60 s); 72°C, 5 min.

[0054] The PCR products were separated by agarose gel electrophoresis, and the 2000 bp DNA band was recovered by gel excision, subcloned into pTOPOT vector, and transformed into DH5α competent cells. The strains identified by PCR were named E. coliDH5α / pTOPOT-full length HMTP210 was sent to Shanghai Bioengineering Co., Ltd. for sequence determination. The results of the determination were subjected to BLAST comparison. The comparison results showed that the amplified fragment was the HMTP210 gene of A. paragallinarum type A, and its nucleotide sequence was shown in SEQ ID NO.8. The amino acid sequence of A. paragallinarum type A HMTP210 protein was shown in SEQ ID NO.3.

[0055] 1.2 Tailoring of the A. paragallinarum HMTP210 gene sequence and its N-terminal antigen epitope fusion

[0056] Since the full-length A. paragallinarum HMTP210 gene is prone to inclusion body expression in a prokaryotic expression system, the protein needs to go through a complex denaturation and renaturation process to re-form the correct folding, which is inefficient and difficult to amplify; in addition, most of the antigenic epitopes of A. paragallinarum HMTP210 are mainly concentrated in the 148-666 amino acid residues, which play an important role in maintaining the conformation of the trimer and forming the correct antigenic structure. Therefore, the DNA sequence corresponding to the C-terminal 148-666 amino acids of the A. paragallinarum HMTP210 gene fragment was amplified by PCR.

[0057] First, design synthetic primers as follows:

[0058] HMTP F2:5'- CCC GGATCC ACTAAAGGGATCTACCTTAAAG-3'(SEQ ID NO.12)

[0059] The italic part is the introduced protective base, and the underlined part is the introduced restriction site of BamH I. Using pTOPOT-full length HMTP210 as a template and HMTP F2 / HMTP R1 as primers, the DNA fragment of A. paragallinarum HMTP (148-666) was amplified, and the amplified fragment size was 1557 bp. The PCR product was analyzed by agarose gel electrophoresis, and the A. paragallinarum HMTP (148-666) fragment was recovered by gel excision.

[0060] The above-recovered A. paragallinarum type A HMTP (148-666) gene fragment and pET28a plasmid were digested with BamH I and Xho I restriction endonucleases, and the double-digestion products were recovered by electrophoresis and then ligated with T4 DNA ligase.

[0061] The ligation product was transformed into competent E. coli BL21 (DE3) cells and screened using kanamycin plates. Single clones were selected for PCR verification and the correct strain was named E. coli BL21(DE3) / pET28a-HMTP(148-666).

[0062] Through analysis and prediction, the nucleotide sequences of the six antigenic epitopes at the N-terminus of the A-type Avian Bacillus paragallinarum HMTP210 gene were found, and two antigenic epitope fragments were selected (the nucleotide sequence of the A-type Avian Bacillus paragallinarum HMTP210 gene as shown in SEQ ID NO.8, positions 222-258: ATTGTTAATGTTGCAGCAGGCGATGTTTCGCAAGCT, corresponding to the amino acid sequence of the A-type Avian Bacillus paragallinarum HMTP210 protein as shown in SEQ ID NO.3, positions 75-68: IVNVAAGDVSQA; the nucleotide sequence of the A-type Avian Bacillus paragallinarum HMTP210 gene as shown in SEQ ID NO.8, positions 307-336: TTGAGCAAAGTGGCTCAATCTGTTAAGAGC, corresponding to the amino acid sequence of the A-type Avian Bacillus paragallinarum HMTP210 protein as shown in SEQ ID NO. The amino acid sequence of the A. paragallinarum HMTP210 protein type A shown in NO.3 (positions 103-112: LSKVAQSVKS) was used for fusion with the A. paragallinarum HMTP (148-666) fragment.

[0063] In order to fuse the antigenic epitope at the N-terminus of A. paragallinarum HMTP (148-666) and retain the antigenic epitope integrity of A. paragallinarum HMTP, the DNA sequence encoding the antigenic epitope was introduced at the 5' end of the forward primer of PCR to achieve this purpose. The synthetic primers were designed as follows:

[0064] HMTP(75-86)F1:5'-GATGTTTCGCAAGCTGGCGGCGGCGGCAGTACTAAAGGGATCTAC-3'(SEQID NO.13)

[0065] HMTP(75-86)F2:5'- CCC GGATCC ATTGTTAATGTTGCAGCAGGCGATGTTTCGCAAGCT-3'(SEQID NO.14)

[0066] HMTP(103-112)F1:5'-CAATCTGTTAAGAGCGGTGGTGGTGGTAGCACTAAAGGGATCTAC-3'(SEQ ID NO.15)

[0067] HMTP(103-112)F2:5'- CCC GGATCC TTGAGCAAAGTGGCTCAATCTGTTAAGAGC-3'(SEQ IDNO.16)

[0068] HMTP(75-86 / 103-112)F1:5'-GATGTTTCGCAAGCTGGCGGCGGCGGCAGTTTGAGCAAAGTGGCT-3'(SEQ ID NO.17)

[0069] Using pET28a-HMTP (148-666) as a template and HMTP (75-86) F1 / HMTP R1 as primers, PCR amplification was performed, and the PCR product was recorded as "a". Using "a" as a template and HMTP (75-86) F2 / HMTP R1 as primers, PCR amplification was performed, and the PCR product was recorded as "b". The target fragment was purified by gel electrophoresis. The DNA fragment was fused with the 75-86 antigen epitope sequence of the amino acid sequence of the Avian Bacillus paragallinarum HMTP210 protein of type A as shown in SEQ ID NO.3 and the DNA sequence corresponding to Linker at the 5' end of Avian Bacillus paragallinarum HMTP (148-666). The fragment was named Avian Bacillus paragallinarum HMTP (75-86 / 148-666) type A, wherein the amino acid sequence of Linker is shown in SEQ ID NO.4, and the nucleotide sequence of Linker is shown in SEQ ID NO.9.

[0070] Linker amino acid sequence (GGGGS, SEQ ID NO.4), Linker nucleotide sequence (GGCGGCGGCGGCAGT, SEQ ID NO.9)

[0071] Using pET28a-HMTP(148-666) as a template and HMTP(103-112)F1 / HMTP R1 as primers, PCR amplification was performed, and the PCR product was recorded as "c". Then, using "c" as a template and HMTP(103-112)F2 / HMTP R1 as primers, PCR amplification was performed, and the PCR product was recorded as "d". The target fragment was purified by gel electrophoresis. The DNA fragment was fused with the 103-112 antigen epitope sequence of the amino acid sequence of the Avian Bacillus paragallinarum HMTP210 protein of type A as shown in SEQ ID NO.3 and the DNA sequence corresponding to the linker at the 5' end of Avian Bacillus paragallinarum HMTP(148-666). The fragment was named Avian Bacillus paragallinarum HMTP(103-112 / 148-666).

[0072] Using "d" as template and HMTP(75-86 / 103-112)F1 / HMTP R1 as primers, PCR amplification was performed, and the PCR product was recorded as "e". Using "e" as template and HMTP(75-86)F2 / HMTP R1 as primers, PCR amplification was performed, and the PCR product was recorded as "f". The target fragment is purified by gel electrophoresis and gel cutting. The DNA fragment is fused with the 75-86 antigenic epitope sequence of the amino acid sequence of Avibacterium paragallinarum HMTP210 protein type A as shown in SEQ ID NO.3-Linker-the DNA sequence corresponding to the 103-112 antigenic epitope sequence of the amino acid sequence of Avibacterium paragallinarum HMTP210 protein type A as shown in SEQ ID NO.3-Linker at the 5' end of Avibacterium paragallinarum HMTP (148-666). The fragment is named Avibacterium paragallinarum HMTP type A, and its DNA sequence is shown in SEQ NO.5. The amino acid sequence of the recombinant Avibacterium paragallinarum HMTP protein is shown in SEQ ID NO.1.

[0073] The Avian Bacillus paragallinarum HMTP and pET28a plasmid were digested with BamH I and Xho I restriction endonucleases, and the digested fragments were separated by electrophoresis and purified by gel cutting. The gene fragments after enzyme digestion and purification were connected with the digested pET28a vector. The ligation product was transformed into Escherichia coli BL21 (DE3) competent cells and screened using kanamycin plates. Single clones were selected for PCR verification, and the verified correct strains were named: E. coli BL21(DE3) / pET28a-HMTP.

[0074] 1.3 Codon optimization of the HMTP gene of A. paragallinarum type A

[0075] because E. coli The expression level was low after induction with BL21(DE3) / pET28a-HMTP. Sequence analysis revealed that the HMTP gene of A. paragallinarum type A contained multiple rare codons that were used less frequently by Escherichia coli. Therefore, the codons of A. paragallinarum type A HMTP needed to be optimized in order to improve the expression level of the recombinant protein while ensuring the soluble expression of A. paragallinarum type A HMTP.

[0076] The codon optimization scheme is shown in Table 1 below: the rare codon ATA at position 59 (the amino acid site corresponding to the Avian Bacillus paragallinarum type A HMTP after pruning) is synonymously replaced by the codon ATT that can be normally recognized by Escherichia coli tRNA, the rare codon CTA at position 179 (the amino acid site corresponding to the Avian Bacillus paragallinarum type A HMTP after pruning) is synonymously replaced by the codon CTG that can be normally recognized by Escherichia coli tRNA, the rare codon AGA at position 237 (the amino acid site corresponding to the Avian Bacillus paragallinarum type A HMTP after pruning) is synonymously replaced by the codon AGC that can be normally recognized by Escherichia coli tRNA, the rare codon CTA at position 381 (the amino acid site corresponding to the Avian Bacillus paragallinarum type A HMTP after pruning) is synonymously replaced by the codon CTG that can be normally recognized by Escherichia coli tRNA, and the rare codon CTA at position 407 (the amino acid site corresponding to the Avian Bacillus paragallinarum type A HMTP after pruning) is synonymously replaced by the codon CTG that can be normally recognized by Escherichia coli tRNA.

[0077] Table 1 Codon optimization scheme for A. paragallinarum HMTP type A

[0078]

[0079] The codon-optimized A. paragallinarum HMTP gene was synthesized and inserted into the BamH I and Xho I sites of the pET28a vector. The expression vector synthesized by the whole gene was named pET28a-HMTPopti. The vector was transformed into the BL21 (DE3) strain and named E. coli BL21(DE3) / pET28a-HMTPopti.

[0080] Example 2 Induced expression, purification and identification of recombinant A. paragallinarum HMTP protein

[0081] The obtained E. coli BL21(DE3) / pET28a-HMTP and E. coli BL21(DE3) / pET28a-HMTPopti strains were activated; after inoculation at 1% inoculum, the cells were cultured at 37°C with shaking for 3 h; lactose was added for induction, the final concentration of lactose was 30 mM, the induction temperature was 32°C, and the induction time was 12 h. After the induction, the cells were collected by centrifugation.

[0082] Add 0.02 mol / L PB buffer with a pH value of 6.8 to the collected bacteria, resuspend and then perform ultrasonic disruption. Centrifuge at 12000g, 4℃ for 10 minutes, collect the supernatant, which is the soluble protein. Use BCA method to determine the protein content, and use SDS-PAGE technology to detect. The results are as follows: Figure 1 shown.

[0083] from Figure 1 It can be seen that E. coli BL21(DE3) / pET28a-HMTP and E. coli The molecular weight of the expression product of BL21(DE3) / pET28a-HMTPopti was consistent with the expectation. Compared with the target protein expressed by E. coli BL21(DE3) / pET28a-HMTP before codon optimization, the expression level of the target protein of E. coli BL21(DE3) / pET28a-HMTPopti after codon optimization was not only significantly increased, but also the solubility level was significantly improved.

[0084] Further, weak cation exchange chromatography was used to purify the recombinant A. paragallinarum HMTP protein. The weak cation chromatography medium used for purification was Sepharose CM Fast Flow, the equilibrium buffer was 0.02mol / LPB buffer with a pH value of 6.8, the elution buffer was 0.02mol / L PB+0.5mol / L NaCl with a pH value of 6.8, and the elution buffer was 0.02mol / L PB+1mol / L NaCl with a pH value of 6.8. The protein eluted by the elution buffer was the recombinant A. paragallinarum HMTP protein.

[0085] The purified product was detected using SDS-PAGE technology. Figure 2 shown.

[0086] from Figure 2 It can be seen that the HMTP protein of A. paragallinarum type A can be purified using weak cation exchange chromatography, which is simple to operate and easy to scale up.

[0087] Example 3 Cloning of the aroA gene of Avibacterium paragallinarum type A, construction of expression strain, and induction and purification of recombinant protein

[0088] 3.1 Cloning and sequencing of the aroA gene of A. paragallinarum type A

[0089] First, the primers for amplifying the aroA gene of Avibacterium paragallinarum type A were synthesized as follows:

[0090] aroA PF1:5'- CCC GGATCC ATGGAAAAATTAACGCTAC-3'(SEQ ID NO.18)

[0091] aroA PR1:5'- CCC CTCGAGTTATCGTACAATCTTCGC-3'(SEQ ID NO.19)

[0092] The italic CCC bases are the restriction site protection bases, and the underlined bases are the introduced restriction sites BamH I and XhoI.

[0093] The genome of the A. paragallinarum HP-8 strain extracted in Example 1 was used as a template, and aroA PF1 / aroAPR1 was used as a primer to perform PCR amplification. The amplified product was subjected to electrophoresis analysis, and a band of about 1300 bp was recovered by gel cutting. The DNA fragment was subcloned into a pTOPO T vector and transformed into a DH5α competent medium, and sequenced after PCR. The sequence was confirmed to be the A. paragallinarum A type A aroA gene of A. paragallinarum by BLAST analysis, and its nucleotide sequence is shown in SEQ ID NO.7, and the amino acid sequence of the recombinant A. paragallinarum aroA protein is shown in SEQ ID NO.2.

[0094] The aroA gene fragment of A. paragallinarum type A was double-digested and ligated with the pET28a vector treated in the same way using T4 DNA ligase. The fragment was transformed into BL21 (DE3) competent cells and the correct single clone was identified and named E. coli BL21(DE3) / pET28a-aroA.

[0095] 3.2 Inducible expression and purification of recombinant A. paragallinarum aroA

[0096] (1) Activation of bacterial strains: Take out the frozen E. coli The BL21(DE3) / pET28a-aroA strain was thawed and transferred into 5 mL of LB liquid medium at a ratio of 0.2%, kanamycin sulfate at a final concentration of 50 μg / mL was added, and the shaker was set at 37°C and 220 rpm for 8 h. After it grew, the bacterial liquid was streaked with an inoculation loop into LB solid medium containing kanamycin sulfate resistance, and cultured at 37°C for 16 h. The grown colonies were picked into 5 mL of LB liquid medium containing kanamycin sulfate resistance, and the shaker was set at 37°C and 220 rpm for 8 h. It was added into 200 mL of LB liquid medium containing kanamycin at a ratio of 1%, and the shaker was set at 37°C and 220 rpm for 8 h.

[0097] (2) Expansion culture: Add the successfully activated bacteria into 300 mL of LB liquid culture medium at a ratio of 2%, with a final concentration of kanamycin sulfate of 50 μg / mL. Set the shaking parameters to 37°C and 220 rpm, and culture on the shaker for 3 h until the OD 600 The value reaches 0.8.

[0098] (3) Inducing expression: Add α-lactose to a final concentration of 30 mmol / L, set the shaking parameters to 32°C and 220 rpm, continue inducing culture for 14 h, use a high-speed centrifuge at 12,000 g for 10 min to collect the bacteria and weigh and record.

[0099] Weigh 1g E. coli BL21(DE3) / pET28a-aroA bacteria, add 40mL of 0.02mol / L PB buffer with a pH value of 8.0 at a ratio of 1:40, then place the plastic beaker into a beaker mixed with ice water, ultrasonically disrupt for 3s, with an interval of 6s and a working time of 30min. Centrifuge at 12000g, 4℃ for 10min, collect the supernatant, and filter the protein solution with a 0.22μm filter.

[0100] Weak anion exchange chromatography was used to purify the recombinant A. paragallinarum aroA protein. The weak anion chromatography medium used for purification was Sepharose DEAE Fast Flow, the equilibrium buffer was 0.02mol / L PB buffer with a pH value of 8.0, the wash buffer was 0.02mol / L PB+0.5mol / L NaCl with a pH value of 8.0, the elution buffer was 0.02mol / L PB+1mol / L NaCl with a pH value of 8.0, and the elution buffer was 0.02mol / L PB+2mol / LNaCl with a pH value of 8.0. The protein eluted by the elution buffer was the recombinant A. paragallinarum aroA protein.

[0101] The protein content was determined using the BCA method, and the protein was identified using the SDS-PAGE method. The results are as follows: Figure 3 shown.

[0102] from Figure 3 From the results, it can be seen that the molecular weight of the aroA protein of A. paragallinarum type A is consistent with expectations and can be effectively purified by weak anion exchange chromatography with high purification efficiency and easy scale-up.

[0103] Example 4 Safety and efficacy test of HMTP genetically engineered subunit vaccine against infectious coryza (type A) in chickens

[0104] 4.1 Preparation of HMTP Genetically Engineered Subunit Vaccine for Infectious Coryza (Type A)

[0105] After the weak cation exchange chromatography purification, the A. paragallinarum HMTP protein was diluted with an appropriate amount of PBS, and formaldehyde was added to a final concentration of 0.037%, and the antigen was inactivated in a refrigerator at 4°C for 72 hours. After the inactivation, a sterility test was performed.

[0106] After the sterility test is passed, mix it with ISA71 VG mineral oil adjuvant at a volume ratio of 1:3 at room temperature to make the target protein 200μg / mL. Use a shearing machine to fully shear at 8000rpm in an ice water bath environment, shear for 4 minutes, and stop for 1 minute. After shearing, check the emulsification. Use a 1mL pipette to vertically drop 1mL on clean water. It is OK if it does not spread from the second drop; take 1mL of the sheared mixture and centrifuge it at 3000g for 15 minutes. If there is no demulsification, it is OK. After the emulsification test is qualified, it is the chicken infectious coryza (type A) HMTP genetic engineering subunit vaccine, which should be stored in a 4℃ refrigerator.

[0107] 4.2 Safety testing of the HMTP genetically engineered subunit vaccine against infectious coryza (type A) in chickens

[0108] Five 30-day-old SPF chickens were used for safety testing. Each chicken was immunized with 2 ml of HMTP genetic engineering subunit vaccine subcutaneously in the neck. The chickens were continuously observed for 14 days after immunization. No obvious adverse reactions were found in the chickens. The chickens were in good mental state. No adverse reactions such as nodules, abscesses and ulcers were found in the autopsy of the injection site. This shows that the HMTP genetic engineering subunit vaccine for infectious coryza (type A) meets the safety standards.

[0109] 4.3 Evaluation of the efficacy of the HMTP genetically engineered subunit vaccine against infectious coryza (type A)

[0110] The SPF eggs were incubated in an incubator and fed to 30 days of age. Thirty 30-day-old SPFs were randomly divided into three groups: immune protection group A, challenge control group B, and blank control group C, with 10 SPF chickens in each group. The immune protection group A was injected subcutaneously with 0.5 ml of HMTP subunit vaccine in the neck, and the challenge control group B and blank control group C were injected with 0.5 ml of normal saline; 21 days after immunization, the immune protection group A and the challenge control group B were injected with 0.2 ml (500 CFU / 0.2 ml) of A. paragallinarum HP-8 strain bacterial solution in the infraorbital sinus, and the blank control group C was not challenged. The clinical symptoms were observed for 7 consecutive days and scored according to the clinical scoring criteria for A. paragallinarum challenge in Table 2 below.

[0111] Table 2 Clinical scoring criteria for Avibacterium paragallinarum challenge

[0112]

[0113] The attack and protection results are shown in Table 3 below, where a clinical symptom score ≥ 2 points (2 points, 3 points, 4 points, 5 points) was considered to be onset, and a score ≤ 1 point (0 point, 1 point) was considered to be non-onset.

[0114] Table 3 Evaluation results of challenge with HMTP genetic engineering subunit vaccine against infectious coryza (type A)

[0115]

[0116] From the results in Table 3, it can be seen that all 10 chickens in the challenge control group became ill, while none of the blank control group became ill. However, 7 of the chickens immunized with the HMTP subunit vaccine did not become ill and 3 became ill, with a challenge protection rate of 70%.

[0117] Example 5 Safety and efficacy testing of aroA genetically engineered subunit vaccine against infectious coryza (type A) in chickens

[0118] 5.1 Preparation of aroA genetically engineered subunit vaccine for infectious coryza (type A)

[0119] After purification by weak anion exchange chromatography, the recombinant aroA protein was diluted with an appropriate amount of PBS, and formaldehyde was added to a final concentration of 0.037%, and the antigen was inactivated in a refrigerator at 4°C for 72 hours. After the inactivation, a sterility test was performed.

[0120] After the sterility test is passed, ISA71 VG adjuvant with 3 times the volume of the antigen is added at room temperature so that the aroA antigen concentration in the mixture is 200 μg / mL. Emulsification is performed using a high-speed shearing machine for 15 minutes. After the emulsification test is passed, it is the chicken infectious coryza (type A) aroA genetic engineering subunit vaccine and is stored in a 4°C refrigerator.

[0121] 5.2 Safety testing of the aroA genetically engineered subunit vaccine against infectious coryza (type A)

[0122] Five 30-day-old SPF chickens were used for safety testing. Each chicken was immunized subcutaneously with a large dose of 2 ml of aroA genetic engineering subunit vaccine in the neck. The chickens were continuously observed for 14 days after immunization. No obvious adverse reactions were found in the chickens. The chickens were in good mental state. No adverse reactions such as nodules, abscesses and ulcers were found in the autopsy of the injection site. This shows that the chicken infectious coryza (type A) aroA genetic engineering subunit vaccine meets the safety standards.

[0123] 5.3 Evaluation of the efficacy of aroA genetically engineered subunit vaccine against infectious coryza (type A)

[0124] The SPF eggs were incubated in an incubator and fed to 30 days of age. Thirty 30-day-old SPFs were randomly divided into three groups: immune protection group D, challenge control group E, and blank control group F, with 10 SPF chickens in each group. The immune protection group D was subcutaneously injected with 0.5 ml of aroA subunit vaccine in the neck, and the challenge control group E and blank control group F were injected with 0.5 ml of normal saline; 21 days after immunization, the immune protection group D and the challenge control group E were injected with 0.2 ml (500 CFU / 0.2 ml) of A. paragallinarum HP-8 strain bacterial solution in the infraorbital sinus, and the blank control group F was not challenged. The clinical symptoms were observed for 7 consecutive days and scored according to the clinical scoring criteria for A. paragallinarum challenge in Table 2.

[0125] The attack and protection results are shown in Table 4 below, where a clinical symptom score ≥ 2 points (2 points, 3 points, 4 points, 5 points) was considered to be onset, and a score ≤ 1 point (0 point, 1 point) was considered to be non-onset.

[0126] Table 4 Evaluation results of challenge with aroA genetically engineered subunit vaccine against infectious coryza (type A)

[0127]

[0128] From the results in Table 4, it can be seen that all 10 chickens in the challenge control group became ill, while none of the blank control group became ill. However, 4 of the chickens immunized with aroA subunit vaccine did not become ill and 6 became ill, with a challenge protection rate of 40%.

[0129] Example 6 Safety and efficacy testing of a genetically engineered subunit vaccine combining HMTP and aroA against infectious coryza (type A) in chickens

[0130] According to the methods in Examples 4 and 5, the Avibacterium paragallinarum type A HMTP and Avibacterium paragallinarum type A aroA antigens were inactivated, the Avibacterium paragallinarum type A HMTP antigen protein and the Avibacterium paragallinarum type A aroA antigen protein were mixed in a certain ratio, and then ISA71 VG adjuvant with a volume of 3 times the mixed antigen was added, and genetically engineered subunit vaccines containing different concentrations of HMTP and aroA were prepared after emulsification. The contents of HMTP and aroA antigens in each vaccine are shown in Table 5 below.

[0131] Table 5 HMTP and aroA antigen content in the 9 vaccines prepared

[0132]

[0133] The SPF eggs were incubated in an incubator and fed to 30 days of age. 110 30-day-old SPF were randomly divided into eleven groups, including combination vaccine groups 1-9, challenge control group 10, and blank control group 11, with 10 SPF chickens in each group. Each group of immune protection groups 1-9 was subcutaneously injected with 1 ml of combination vaccine 1-9, and challenge control group 10 and blank control group 11 were injected with 0.5 ml of normal saline; 21 days after immunization, the immune protection groups 1-9 and challenge control group 10 were injected with 0.2 ml (500 CFU / 0.2 ml) of A. paragallinarum HP-8 strain bacterial solution in the infraorbital sinus, and the blank control group 11 was not challenged. The clinical symptoms were observed for 7 consecutive days and scored according to the clinical scoring criteria for A. paragallinarum challenge in Table 2.

[0134] The results of attack and protection are shown in Table 6 below, where a clinical symptom score ≥ 2 points (2 points, 3 points, 4 points, 5 points) was considered to be onset, and a score ≤ 1 point (0 point, 1 point) was considered to be non-onset.

[0135] Table 6 Evaluation results of the genetically engineered subunit vaccine challenge with HMTP and aroA combination

[0136]

[0137] From the results in Table 6, it can be seen that all 10 chickens in the challenge control group were sick, with a clinical symptom score of 3.2; none of the blank control group was sick, with a clinical symptom score of 0.1; the challenge protection rates of the vaccine combined with HMTP and aroA were 60%, 70%, 80%, 80%, 90%, 90%, 90%, 100%, and 100%, respectively, and the clinical symptom scores were 1.2, 1.0, 0.8, 0.8, 0.6, 0.5, 0.4, 0.2, and 0.1, respectively. With the increase of the amount of HMTP and aroA antigens, the immune protection rate increased and the clinical symptoms were alleviated; the combination of HMTP and aroA antigens has a positive synergistic effect. Under the same antigen dose, the combined vaccine of HMTP and aroA antigens has a higher challenge protection than the single antigen vaccine; when the HMTP antigen content is ≥100μg / mL and the aroA antigen content is ≥50μg / mL, the challenge protection of the vaccine is the highest.

[0138] In summary, the present invention cuts 147 amino acid residues from the N-terminus of the A. paragallinarum HMTP210 protein as shown in SEQ ID NO.3 to obtain a core sequence of the amino acid sequence at positions 148-666, and then fuses the antigen epitope sequence at the N-terminus of the core sequence to obtain a recombinant A. paragallinarum HMTP protein. The recombinant A. paragallinarum HMTP protein has good solubility and good immunogenicity. After being prepared into a genetically engineered subunit vaccine, it has good protective efficacy against infectious coryza (type A). Furthermore, after the recombinant A. paragallinarum HMTP protein and the recombinant A. paragallinarum aroA protein are mixed in a specific ratio, the prepared genetically engineered subunit vaccine composition has better protective efficacy against infectious coryza (type A).

[0139] It should be noted that the above embodiments all belong to the same inventive concept, and the description of each embodiment has its own focus. For matters that are not described in detail in some embodiments, reference may be made to the description in other embodiments.

[0140] The above-mentioned embodiments only express the implementation methods of the present invention, and the descriptions thereof are relatively specific and detailed, but they cannot be understood as limiting the scope of the invention patent. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. A recombinant Avibacterium paragallinarum type A HMTP protein, characterized in that: The recombinant A. paragallinarum HMTP protein is obtained by removing 147 amino acid residues from the N-terminus of the A. paragallinarum HMTP210 protein as shown in SEQ ID NO.3 to obtain a core sequence of amino acid sequences at positions 148 to 666, and then fusing an antigen epitope sequence to the N-terminus of the core sequence; The antigen epitope sequence includes the amino acid sequence at positions 75-86 and the amino acid sequence at positions 103-112 of the Avibacterium paragallinarum HMTP210 protein of type A as shown in SEQ ID NO.3; the fusion operation includes: connecting using a linker, the amino acid sequence of the linker is shown in SEQ ID NO.4; The amino acid sequence of the recombinant A. paragallinarum HMTP protein is shown in SEQ ID NO.

1.

2. The nucleic acid molecule encoding the recombinant Avibacterium paragallinarum type A HMTP protein according to claim 1, characterized in that: The nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO.5 or SEQ ID NO.6; wherein the nucleotide sequence shown in SEQ ID NO.6 is obtained by codon-optimizing the nucleotide sequence shown in SEQ ID NO.

5.

3. A biomaterial, characterized in that: The biological material is selected from any one of the following: A1) an expression cassette comprising the nucleic acid molecule according to claim 2; A2) a recombinant vector comprising the nucleic acid molecule according to claim 2; A3) A recombinant cell comprising the nucleic acid molecule or the recombinant vector according to claim 2.

4. A genetically engineered subunit vaccine for infectious coryza in chickens, characterized in that: It comprises the recombinant Avibacterium paragallinarum type A HMTP protein according to claim 1.

5. The genetically engineered subunit vaccine according to claim 4, characterized in that: Also included are medically acceptable carriers, which include adjuvants.

6. A genetically engineered subunit vaccine composition for chicken infectious coryza, characterized in that: The method comprises the recombinant A. paragallinarum type A HMTP protein, the recombinant A. paragallinarum type A aroA protein and a medically acceptable carrier according to claim 1; Among them, the amino acid sequence of the recombinant A. paragallinarum aroA protein is shown as SEQ ID NO.2, and the nucleotide sequence of the nucleic acid molecule encoding the recombinant A. paragallinarum aroA protein is shown as SEQ ID NO.

7.

7. The method for preparing the genetically engineered subunit vaccine composition for infectious coryza in chickens according to claim 6, characterized in that: The steps include: S1, respectively constructing a recombinant vector containing a nucleic acid molecule encoding a recombinant A. paragallinarum HMTP protein and a nucleic acid molecule encoding a recombinant A. paragallinarum aroA protein, and then transforming them into a host cell to obtain a recombinant cell; S2, culturing the recombinant cells respectively, inducing expression to obtain cultures, and separating and purifying the recombinant A. paragallinarum HMTP protein and the recombinant A. paragallinarum aroA protein from the cultures respectively; S3. Mixing the recombinant A. paragallinarum type A HMTP protein and / or the recombinant A. paragallinarum type A aroA protein with an adjuvant to obtain a genetically engineered subunit vaccine composition for infectious coryza.

8. Use of the recombinant Avibacterium paragallinarum type A HMTP protein of claim 1, the nucleic acid molecule of claim 2, the biological material of claim 3, the genetically engineered subunit vaccine for infectious coryza in chickens of claim 4, and the genetically engineered subunit vaccine composition for infectious coryza in chickens of claim 6 in the preparation of a medicament for preventing and / or treating infectious coryza in chickens.